Developer docs
API playgroundTry for free, no card

Search company profiles

Prondil

Full company profile

uuid000hclv

Namestring
Prondil
Legal namestring
Prondil S.A.
Websiteurl
prondil.com
Company typeenum
Private
Founded yearint
1990
Descriptiontext

Prondil S.A. is a Uruguayan biotechnology company founded in the early 1990s by former executives of Cooper Animal Health (formerly Wellcome Research Laboratories), specializing exclusively in the development and production of veterinary vaccines and antigens for animal health. The company manufactures biological products — primarily clostridial bacterins/toxoids, Pasteurella and Mannheimia vaccines, anthrax vaccines, and botulism vaccines — for cattle, sheep, goats, pigs, horses, and camels. Its pipeline includes recombinant vaccine technology targeting infectious pancreatic necrosis in salmon (Project PIEP) and viral antigen development for bovine vaccines (Project Alianza) conducted jointly with Universidad de la República's Faculty of Sciences.

The product portfolio comprises roughly 18 branded SKUs organized under the PRONDICLOS (polyclostridial), PRONDIVAX (specialty clostridial combinations), PRONDIBOT, PRONDIPAST, PRONDISTAR, PRONDITHRAX, and PRONDIVAC lines. Production takes place at a single biosecure manufacturing facility in Montevideo under US CFR, European Pharmacopeia (PhEur), OIE, WHO, and Mercosur GMP standards, which supports export-grade quality credentials.

Prondil generates revenue through one-time product sales of veterinary vaccines and antigens, distributing both directly via its international sales force and indirectly through strategic alliances with major multinational veterinary companies that re-sell the same products under partner commercial names. End customers include livestock producers, veterinarians, and livestock technicians across more than 20 countries. Since December 2017, Prondil has operated as a wholly-owned subsidiary of MSD Animal Health (a Merck & Co. subsidiary), which provides global distribution leverage but also concentrates strategic decision-making with the parent. Public pricing is not disclosed; commercial inquiries route through a Merck email address, consistent with the integrated post-acquisition sales posture.

Short descriptiontext

Prondil S.A. is a Uruguayan biotech manufacturer of veterinary vaccines and antigens — primarily clostridial, pasteurella, anthrax, and botulism vaccines for livestock — exporting to over 20 countries as a wholly-owned subsidiary of MSD Animal Health since 2017.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
51–100
akta.pro rankint
HeadquartersMontevideo, Uruguay
HQ citystring
Montevideo
HQ countrystring
Uruguay
HQ regionstring
Latin America
Markets served

Serves global market

Offices1 record

Each record includes

City, Country, Type, Description, Source

Keyword5 values
veterinary vaccines, animal health biotechnology, veterinary biologicals, livestock immunization, recombinant vaccine technology
Industry4 codes
PRIMARYHLAMAKAB
Livestock Vaccines (Cattle, Swine, Sheep & Goats)
SECONDARYHLAMAEAL
Veterinary Vaccines (Biologics)
Healthcare & Life Sciences/Veterinary & Animal Health/Veterinary Pharmaceuticals & Biologics
SECONDARYHLAMAKAM
Vaccine R&D, Clinical/Field Trials & Regulatory Affairs
SECONDARYAFAEANAK
Veterinary Pharmacy, Vaccine & Biologics Services
NAICS code1 code
  • Pharmaceutical Preparation Manufacturing325412
SIC code1 code
  • Pharmaceutical Preparations2834
Product category
Veterinary Vaccines
Social media profiles1 record
GTM motion2 records

Each record includes

Type, Description, Source

Revenue model1 record
1Veterinary vaccines and antigens
TypeOne Time License
Description

Prondil manufactures and exports veterinary biological products (vaccines and antigens) for animal health. Products are sold in over 20 countries both under the Prondil brand and under other commercial names, working in co-operation with major multinational veterinary companies.

prondil.com
Marketing channels4 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels3 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components6 values
Personnel, Operations, Technology or R&D, Supply Chain, Infrastructure, Marketing or Sales
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Brand1 of 18 records shown
1PRONDIBOT
Description

Vaccine for active immunization against Botulism for cattle, sheep, horses and goats

prondil.com
+17 more records
Core offering1 text field

Prondil is a biotechnology company that develops and manufactures veterinary vaccines and antigens for animal health, with 100% of its technical efforts focused on biological products. Its portfolio covers clostridial diseases (Blackleg, Enterotoxaemia, Tetanus, Botulism, Malignant Oedema, Pulpy Kidney), pasteurellosis, and anthrax across cattle, sheep, goats, pigs, horses, and camels. The company also pursues recombinant vaccine technology, including a project (PIEP) targeting infectious pancreatic necrosis in salmon.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 value
  • Vaccines have proven highly effective in each of the markets in which Prondil participates, with field results supporting product quality.
Product overview1 text field

Prondil is a biotechnology company specializing in the development and production of high-quality veterinary vaccines and antigens for animal health. The product portfolio consists of multiple branded vaccine families targeting clostridial diseases, pasteurellosis, anthrax, and botulism across cattle, sheep, goats, horses, pigs, and camels. The core products include the PRONDICLOS line (polyclostridial vaccines in various formulations including PRONDICLOS, PRONDICLOS 10, PRONDICLOS B, PRONDICLOS P, PRONDICLOS P MAX, and PRONDICLOS PLUS), the PRONDIVAX line (specialized vaccines including BLACKQUARTER, BLACKQUARTER + ANTHRAX, BLACKQUARTER + BOTULISM, BOTULISM + ANTHRAX, MULTICLOSTRIDIAL 8, and PULPY KIDNEY variants), standalone vaccines (PRONDIBOT, PRONDITHRAX, PRONDIPAST, PRONDISTAR, PRONDIVAC TRIPLE BACTERINA), and antigen products. Products are available under Prondil's own brand and through partnerships with major multinational veterinary companies, distributed across over 20 countries worldwide.

Product and service1 record
1PRONDIBOT
Scale indicator3 records

Each record includes

Type, Value, Description, Source

Partnership6 partners
1Faculty of Sciences (Universidad de la República, Uruguay)
Strategic tierCoreTypeStrategic or Co-development Partner
Description

Prondil maintains a constant relationship with the academic sector. The company has formed alliances with the Faculty of Sciences for joint R&D projects, including Project Alianza for the development of viral antigens for vaccine production, in collaboration with the Virology Section of the Faculty of Sciences.

prondil.com
2Faculty of Medicine (Universidad de la República, Uruguay)
Strategic tierMinorTypeStrategic or Co-development Partner
Description

Joint R&D projects and development activities carried out with research groups from the Faculty of Medicine for new products and improvement of existing processes.

prondil.com
3Faculty of Chemistry (Universidad de la República, Uruguay)
Strategic tierMinorTypeStrategic or Co-development Partner
Description

Collaborative R&D projects with research groups from the Faculty of Chemistry for product development and process improvement in biological production.

prondil.com
4Faculty of Veterinary Science (Universidad de la República, Uruguay)
Strategic tierMinorTypeStrategic or Co-development Partner
Description

Joint development projects for new products and improvement of existing processes carried out with research groups from the Faculty of Veterinary Science.

prondil.com
Strategic tierMinorTypeStrategic or Co-development Partner
Description

Collaborative R&D projects carried out with research groups from ORT University as part of Prondil's strategy to strengthen research and development through academic sector alliances.

Strategic tierCoreTypeStrategic or Co-development Partner
Description

In August 2016, Prondil hosted a training course at its facilities on viral vaccine control techniques for bovine viral vaccines. The course was conducted by Dr. Viviana Parreño and Dr. Marina Bok of INTA Argentina, who are sector references and designers of various technical guides approved under CAMEVET. The 3-day training covered different methodologies to evaluate the potency of bovine viral vaccines for Development and Quality Control staff.

Recent move6 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight6 records

Each record includes

Type, Description

Peers10 records
TypeDirect peer
Description

Independent global animal health company specializing in vaccines and pharmaceuticals for livestock and companion animals, with a meaningful clostridial and bacterial vaccine portfolio. Closely comparable mid-sized competitor in livestock biologicals.

TypeDirect peer
Description

Global animal health and nutrition company with a livestock vaccine portfolio and significant presence in emerging markets. Comparable as a peer in livestock biologicals, particularly in regions Prondil exports to.

TypeRegional player
Description

South African veterinary and human vaccine manufacturer with livestock vaccine exports across Africa. Comparable as an emerging-market veterinary biologics producer serving similar export-driven, price-sensitive livestock markets.

TypeDirect peer
Description

Independent French animal health company with livestock and companion animal pharmaceutical and biological product portfolios. Comparable as a mid-sized peer focused on veterinary medicines including vaccines for cattle and small ruminants.

TypeDirect peer
Description

Latin American veterinary biologics company specializing in livestock vaccines, including foot-and-mouth disease and clostridial products, with strong regional distribution. Highly comparable regional peer competing in the same geographies and species categories as Prondil.

TypeBroad incumbent
Description

Global leader in animal health and medicines, including a broad livestock vaccine portfolio (clostridial, respiratory, reproductive). Directly comparable as a livestock vaccine manufacturer serving cattle, sheep, goats, and pigs across global markets.

TypeDirect peer
Description

Global animal health company headquartered in France with strong livestock vaccine franchises, particularly in poultry and ruminants. Comparable as a privately-held, internationally focused veterinary biologics manufacturer competing in similar clostridial and bacterial disease segments.

TypeEmerging player
Description

Subsidiary of the National Dairy Development Board of India producing veterinary vaccines and human biologicals, with growing international export presence. Comparable as an emerging regional biologics manufacturer exporting to multiple geographies.

TypeBroad incumbent
Description

Major global animal health company with livestock vaccine, parasiticides, and therapeutic offerings. Comparable as a peer in the broader veterinary biologics and pharmaceuticals space, including clostridial and respiratory vaccines for cattle and small ruminants.

10Boehringer Ingelheim Animal Health
TypeBroad incumbent
Description

Top-three global animal health company with extensive livestock and poultry vaccine portfolios and significant recombinant vaccine capabilities. Comparable as a competing multinational veterinary biologics manufacturer with global distribution.

Market position
Strengths4 records

Each record includes

Headline, Details, Source

Weaknesses4 records

Each record includes

Headline, Details, Source

Competitive moat5 records

Each record includes

Type, Details

Key risks5 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Segment3 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile3 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature4 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles2 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
Compliance5 records

Each record includes

Name, Class, Description

Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Prondil

Veterinary Vaccinesprondil.com

Prondil S.A. is a Uruguayan biotech manufacturer of veterinary vaccines and antigens — primarily clostridial, pasteurella, anthrax, and botulism vaccines for livestock — exporting to over 20 countries as a wholly-owned subsidiary of MSD Animal Health since 2017.

What Prondil does

Prondil S.A. is a Uruguayan biotechnology company founded in the early 1990s by former executives of Cooper Animal Health (formerly Wellcome Research Laboratories), specializing exclusively in the development and production of veterinary vaccines and antigens for animal health. The company manufactures biological products — primarily clostridial bacterins/toxoids, Pasteurella and Mannheimia vaccines, anthrax vaccines, and botulism vaccines — for cattle, sheep, goats, pigs, horses, and camels. Its pipeline includes recombinant vaccine technology targeting infectious pancreatic necrosis in salmon (Project PIEP) and viral antigen development for bovine vaccines (Project Alianza) conducted jointly with Universidad de la República's Faculty of Sciences.

The product portfolio comprises roughly 18 branded SKUs organized under the PRONDICLOS (polyclostridial), PRONDIVAX (specialty clostridial combinations), PRONDIBOT, PRONDIPAST, PRONDISTAR, PRONDITHRAX, and PRONDIVAC lines. Production takes place at a single biosecure manufacturing facility in Montevideo under US CFR, European Pharmacopeia (PhEur), OIE, WHO, and Mercosur GMP standards, which supports export-grade quality credentials.

Prondil generates revenue through one-time product sales of veterinary vaccines and antigens, distributing both directly via its international sales force and indirectly through strategic alliances with major multinational veterinary companies that re-sell the same products under partner commercial names. End customers include livestock producers, veterinarians, and livestock technicians across more than 20 countries. Since December 2017, Prondil has operated as a wholly-owned subsidiary of MSD Animal Health (a Merck & Co. subsidiary), which provides global distribution leverage but also concentrates strategic decision-making with the parent. Public pricing is not disclosed; commercial inquiries route through a Merck email address, consistent with the integrated post-acquisition sales posture.

Prondil firmographics

Firmographics
Name
Prondil
Legal name
Prondil S.A.
Website
https://prondil.com
Company type
Private
Founded year
1990
Operating status
Operating
Headcount range
51–100 employees
Short description
Prondil S.A. is a Uruguayan biotech manufacturer of veterinary vaccines and antigens — primarily clostridial, pasteurella, anthrax, and botulism vaccines for livestock — exporting to over 20 countries as a wholly-owned subsidiary of MSD Animal Health since 2017.
Ownership category
akta.pro rank

Prondil industry classification

Industry
Product category
Veterinary Vaccines
NAICS
Pharmaceutical Preparation Manufacturing (325412)
SIC
Pharmaceutical Preparations (2834)
akta.pro industry
PRIMARYHLAMAKAB
Livestock Vaccines (Cattle, Swine, Sheep & Goats)
SECONDARYHLAMAEAL
Veterinary Vaccines (Biologics)
Healthcare & Life Sciences/Veterinary & Animal Health/Veterinary Pharmaceuticals & Biologics
SECONDARYHLAMAKAM
Vaccine R&D, Clinical/Field Trials & Regulatory Affairs
SECONDARYAFAEANAK
Veterinary Pharmacy, Vaccine & Biologics Services

Keywords

  • Veterinary vaccines
  • Animal health biotechnology
  • Veterinary biologicals
  • Livestock immunization
  • Recombinant vaccine technology

Where Prondil is headquartered

Location

Headquarters

HQ city
Montevideo
HQ country
Uruguay
HQ region
Latin America

Offices1 record

Markets served

Prondil business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Personnel, Operations, Technology or R&D, Supply Chain, Infrastructure, Marketing or Sales

Revenue model

  1. Veterinary vaccines and antigens: Prondil manufactures and exports veterinary biological products (vaccines and antigens) for animal health. Products are sold in over 20 countries both under the Prondil brand and under other commercial names, working in co-operation with major multinational veterinary companies.

Go-to-market motion2 records

Distribution channels3 records

Marketing channels4 records

Prondil product offering

Product offering

Core offering

Prondil is a biotechnology company that develops and manufactures veterinary vaccines and antigens for animal health, with 100% of its technical efforts focused on biological products. Its portfolio covers clostridial diseases (Blackleg, Enterotoxaemia, Tetanus, Botulism, Malignant Oedema, Pulpy Kidney), pasteurellosis, and anthrax across cattle, sheep, goats, pigs, horses, and camels. The company also pursues recombinant vaccine technology, including a project (PIEP) targeting infectious pancreatic necrosis in salmon.

Product overview

Prondil is a biotechnology company specializing in the development and production of high-quality veterinary vaccines and antigens for animal health. The product portfolio consists of multiple branded vaccine families targeting clostridial diseases, pasteurellosis, anthrax, and botulism across cattle, sheep, goats, horses, pigs, and camels. The core products include the PRONDICLOS line (polyclostridial vaccines in various formulations including PRONDICLOS, PRONDICLOS 10, PRONDICLOS B, PRONDICLOS P, PRONDICLOS P MAX, and PRONDICLOS PLUS), the PRONDIVAX line (specialized vaccines including BLACKQUARTER, BLACKQUARTER + ANTHRAX, BLACKQUARTER + BOTULISM, BOTULISM + ANTHRAX, MULTICLOSTRIDIAL 8, and PULPY KIDNEY variants), standalone vaccines (PRONDIBOT, PRONDITHRAX, PRONDIPAST, PRONDISTAR, PRONDIVAC TRIPLE BACTERINA), and antigen products. Products are available under Prondil's own brand and through partnerships with major multinational veterinary companies, distributed across over 20 countries worldwide.

Differentiator

Problem solved

Functional benefit

Brands

  • PRONDIBOT: Vaccine for active immunization against Botulism for cattle, sheep, horses and goats
  • PRONDICLOS
  • PRONDICLOS 10
  • PRONDICLOS B
  • PRONDICLOS P
  • PRONDICLOS P MAX
  • PRONDICLOS PLUS
  • PRONDIPAST
  • PRONDISTAR
  • PRONDITHRAX
  • PRONDIVAC TRIPLE BACTERINA
  • PRONDIVAX BLACKQUARTER
  • PRONDIVAX BLACKQUARTER + ANTHRAX
  • PRONDIVAX BLACKQUARTER + BOTULISM
  • PRONDIVAX BOTULISM + ANTHRAX
  • PRONDIVAX MULTICLOSTRIDIAL 8
  • PRONDIVAX PULPY KIDNEY
  • PRONDIVAX PULPY KIDNEY 1 SHOT

Products and services

  • PRONDIBOT

Quantifiable outcome

  • Vaccines have proven highly effective in each of the markets in which Prondil participates, with field results supporting product quality.

Companies that use Prondil

Customer profile

Segments3 records

Ideal customer profiles3 records

Prondil technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature4 records

Prondil partnerships and signals

Strategic signal

Partnerships

Six partnerships are on record, tiered core and minor.

  • Faculty of Sciences (Universidad de la República, Uruguay)coreStrategic or Co-development PartnerProndil maintains a constant relationship with the academic sector. The company has formed alliances with the Faculty of Sciences for joint R&D projects, including Project Alianza for the development of viral antigens for vaccine production, in collaboration with the Virology Section of the Faculty of Sciences.
  • Faculty of Medicine (Universidad de la República, Uruguay)minorStrategic or Co-development PartnerJoint R&D projects and development activities carried out with research groups from the Faculty of Medicine for new products and improvement of existing processes.
  • Faculty of Chemistry (Universidad de la República, Uruguay)minorStrategic or Co-development PartnerCollaborative R&D projects with research groups from the Faculty of Chemistry for product development and process improvement in biological production.
  • Faculty of Veterinary Science (Universidad de la República, Uruguay)minorStrategic or Co-development PartnerJoint development projects for new products and improvement of existing processes carried out with research groups from the Faculty of Veterinary Science.
  • ORT University (Universidad ORT, Uruguay)minorStrategic or Co-development PartnerCollaborative R&D projects carried out with research groups from ORT University as part of Prondil's strategy to strengthen research and development through academic sector alliances.
  • INTA (Instituto Nacional de Tecnología Agropecuaria, Argentina)coreStrategic or Co-development PartnerIn August 2016, Prondil hosted a training course at its facilities on viral vaccine control techniques for bovine viral vaccines. The course was conducted by Dr. Viviana Parreño and Dr. Marina Bok of INTA Argentina, who are sector references and designers of various technical guides approved under CAMEVET. The 3-day training covered different methodologies to evaluate the potency of bovine viral vaccines for Development and Quality Control staff.

Scale indicators3 records

Recent moves6 records

Expansion highlights6 records

Prondil competitors and assessment

Company assessment

Direct peers

  • Virbac: Independent global animal health company specializing in vaccines and pharmaceuticals for livestock and companion animals, with a meaningful clostridial and bacterial vaccine portfolio. Closely comparable mid-sized competitor in livestock biologicals.
  • Phibro Animal Health: Global animal health and nutrition company with a livestock vaccine portfolio and significant presence in emerging markets. Comparable as a peer in livestock biologicals, particularly in regions Prondil exports to.
  • Vetoquinol: Independent French animal health company with livestock and companion animal pharmaceutical and biological product portfolios. Comparable as a mid-sized peer focused on veterinary medicines including vaccines for cattle and small ruminants.
  • Biogénesis Bagó: Latin American veterinary biologics company specializing in livestock vaccines, including foot-and-mouth disease and clostridial products, with strong regional distribution. Highly comparable regional peer competing in the same geographies and species categories as Prondil.
  • Ceva Santé Animale: Global animal health company headquartered in France with strong livestock vaccine franchises, particularly in poultry and ruminants. Comparable as a privately-held, internationally focused veterinary biologics manufacturer competing in similar clostridial and bacterial disease segments.

Regional players

  • Biovac (South Africa): South African veterinary and human vaccine manufacturer with livestock vaccine exports across Africa. Comparable as an emerging-market veterinary biologics producer serving similar export-driven, price-sensitive livestock markets.

Broad incumbents

  • Zoetis: Global leader in animal health and medicines, including a broad livestock vaccine portfolio (clostridial, respiratory, reproductive). Directly comparable as a livestock vaccine manufacturer serving cattle, sheep, goats, and pigs across global markets.
  • Elanco Animal Health: Major global animal health company with livestock vaccine, parasiticides, and therapeutic offerings. Comparable as a peer in the broader veterinary biologics and pharmaceuticals space, including clostridial and respiratory vaccines for cattle and small ruminants.
  • Boehringer Ingelheim Animal Health: Top-three global animal health company with extensive livestock and poultry vaccine portfolios and significant recombinant vaccine capabilities. Comparable as a competing multinational veterinary biologics manufacturer with global distribution.

Emerging players

  • Indian Immunologicals Limited: Subsidiary of the National Dairy Development Board of India producing veterinary vaccines and human biologicals, with growing international export presence. Comparable as an emerging regional biologics manufacturer exporting to multiple geographies.

Market position

Strengths4 records

Weaknesses4 records

Competitive moat5 records

Key risks5 records

Key highlights7 records

Customer concentration

Prondil social profiles

Digital presence

Prondil compliance and trust

Trust signal

Compliance5 records

Prondil financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Prondil leadership team

Management profile

Number of profiles

Profiles2 records

Prondil funding detail

Funding detail

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Prondil M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Prondil

What does Prondil do?

Prondil is a biotechnology company that develops and manufactures veterinary vaccines and antigens for animal health, with 100% of its technical efforts focused on biological products. Its portfolio covers clostridial diseases (Blackleg, Enterotoxaemia, Tetanus, Botulism, Malignant Oedema, Pulpy Kidney), pasteurellosis, and anthrax across cattle, sheep, goats, pigs, horses, and camels. The company also pursues recombinant vaccine technology, including a project (PIEP) targeting infectious pancreatic necrosis in salmon.

Is Prondil a public or private company?

Prondil is a private company. It is classified as corporate owned and is currently operating.

When was Prondil founded?

Prondil was founded in 1990. It employs 51 to 100 people.

Where is Prondil based?

Prondil is headquartered in Montevideo, Uruguay, in the Latin America region.

How does Prondil make money?

One revenue line is on record: veterinary vaccines and antigens.

Who are Prondil's main competitors?

Direct peers on record are Virbac, Phibro Animal Health, Vetoquinol, Biogénesis Bagó and Ceva Santé Animale. Biovac (South Africa) is listed as a regional player. Broad incumbents are Zoetis, Elanco Animal Health and Boehringer Ingelheim Animal Health. Indian Immunologicals Limited is listed as an emerging player.

Does Prondil have an API?

No public API is recorded for Prondil.

What industry is Prondil in?

Prondil's product category is Veterinary Vaccines. Its primary akta.pro industry code is HLAMAKAB, Livestock Vaccines (Cattle, Swine, Sheep & Goats), with a secondary code of HLAMAEAL, Veterinary Vaccines (Biologics). Its NAICS code is 325412 and its SIC code is 2834.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales